Boehringer Ingelheim Corporation Release: First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for linagliptin in Type 2 Diabetes
7/31/2013 9:46:28 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with Type 2 Diabetes at risk of cardiovascular and renal events.
Help employers find you! Check out all the jobs and post your resume.
comments powered by